Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma

Taylor J Aiken1,2, Amy K Erbe,2 Lauren Zebertavage,2 David Komjathy,2 Arika S Feils,2 Matthew Rodriguez,2 Ashley Stuckwisch,2 Stephen D Gillies,3 Zachary S Morris,2 Jen Birstler,4 Alexander L Rakhmilevich,2,5 Paul M Sondel1,2,5

ABSTRACT

Background Most pediatric cancers are considered immunologically cold with relatively few responding to immune checkpoint inhibition. We recently described an effective combination radio-immunotherapy treatment regimen (combination adaptive-innate immunotherapy regimen (CAIR)) targeting adaptive and innate immunity in 9464D-GD2, an immunologically cold model of neuroblastoma. Here, we characterize the mechanism of CAIR and the role of major histocompatibility complex class I (MHC-I) in the treatment response.

Methods Mice bearing GD2-expressing 9464D-GD2 tumors were treated with CAIR (external beam radiotherapy, hu14.18-IL2 immunocytokine, Cpg, anti-CD40, and anti-CTLA4) and tumor growth and survival were tracked. Depletion of specific immune cell lineages, as well as testing in immunodeficient R2G2 mice, were used to determine the populations necessary for treatment efficacy. Induction of MHC-I expression in 9464D-GD2 cells in response to interferon-γ (IFN-γ) and CAIR was measured in vitro and in vivo, respectively, by flow cytometry and quantitative real-time PCR. A cell line with IFN-γ-inducible MHC-I expression (9464D-GD2-I) was generated by transfecting a subclone of the parental cell line capable of expressing MHC-I with GD2 synthase and was used in vivo to assess the impact of MHC-I expression on responsiveness to CAIR.

Results CAIR cures some mice bearing small (50 mm3) but not larger (100 mm3) 9464D-GD2 tumors and these cured mice develop weak memory responses against tumor rechallenge. Early suppression of 9464D-GD2 tumors by CAIR does not require T or natural killer (NK) cells, but eventual tumor cures are NK cell dependent. Unlike the parental 9464D cell line, 9464D-GD2 cells have uniformly very low MHC-I expression at baseline and fail to upregulate expression in response to IFN-γ. In contrast, 9464D-GD2-I upregulates MHC-I in response to IFN-γ and is less responsive to CAIR.

Conclusion Treatment with CAIR cures 9464D-GD2 tumors in a NK cell dependent manner and induction of MHC-I by tumors cells was associated with decreased efficacy. These results demonstrate that the early tumor response to this regimen is T and NK cell independent, but that NK cells have a role in generating lasting cures in the absence of MHC-I expression by tumor cells. Further strategies to better inhibit tumor outgrowth may require further NK activation or the ability to engage alternative immune effector cells.

WHAT IS ALREADY KNOWN ON THIS TOPIC

A combination radio-immunotherapy regimen (external beam radiotherapy, hu14.18-IL2 immunocytokine, Cpg, anti-CD40, and anti-CTLA4) is effective in immunologically cold 9464D-GD2 murine neuroblastoma.

WHAT THIS STUDY ADDS

Natural killer (NK) cells are a primary effector population responsible for the responsiveness of 9464D-GD2 tumors to combination radio-immunotherapy and their activity might be aided by very low expression of major histocompatibility complex class I on the surface of 9464D-GD2 cells. Further strategies to better inhibit tumor outgrowth may require further NK activation or the ability to engage alternative immune effector cells.

INTRODUCTION

Neuroblastoma is the most common extracranial solid tumor in pediatrics. High-risk cases, which account for approximately half of all patients, are associated with a 5-year overall survival rate of 50%.1,2 Tumor-specific monoclonal antibodies (mAb) targeting GD2, a disialoganglioside preferentially upregulated on tumors of neuroectodermal origin, including neuroblastoma and melanoma, are a component of standard therapy for high-risk neuroblastoma patients following combination chemotherapy, surgical resection, and autologous stem cell transplant.3 Despite this multimodal strategy, the risk of relapse remains high, highlighting an opportunity...
for an enhanced immunotherapeutic approach to reduce the risk of recurrence.

We previously described a combination radio-immunotherapy regimen, which activates components of both the adaptive and innate immune systems to induce tumor cures in an immunologically cold model of neuroblastoma. Herein, this combination adaptive-innate immunotherapy regimen is referred to as ‘CAIR’. The foundation of this approach is the hu14.18-IL2 immunocytokine (IC), a fusion protein linking hu14.18 anti-GD2 mAb and interleukin (IL)-2. When immunocytokine is delivered intratumorally (IT-IC) in combination with local radiation therapy (12 Gy RT), this approach generates an in situ vaccination effect that cures mice bearing GD2-expressing B78 melanoma and NXS2 neuroblastoma. The treatment efficacy was enhanced by concurrent immune checkpoint inhibition with anti-CTLA4 antibodies. However, this RT + IT-IC approach is not effective, even when anti-CTLA4 is added, in mice bearing 9464D-GD2 neuroblastoma tumors, which are immunologically cold and are associated with low tumor mutation burden.

Separately, we have described an effective combination of innate-targeting (agonistic anti-CD40 mAb and CpG-oligodeoxynucleotides) and adaptive-targeting (IT-IC) combination (IT-IC) in combination with local radiation therapy (12 Gy RT), this approach generates an in situ vaccination effect that cures mice bearing GD2-expressing B78 melanoma and NXS2 neuroblastoma. The treatment efficacy was enhanced by concurrent immune checkpoint inhibition with anti-CTLA4 antibodies. However, this RT + IT-IC approach is not effective, even when anti-CTLA4 is added, in mice bearing 9464D-GD2 neuroblastoma tumors, which are immunologically cold and are associated with low tumor mutation burden.

Separately, we have described an effective combination of innate-targeting (agonistic anti-CD40 mAb and CpG-oligodeoxynucleotides) and adaptive-targeting (IT-IC and anti-CTLA4 mAb) approaches to cure tumors in a murine model of melanoma. When we added local RT to this treatment combination (ie, CAIR), it was able to cure some mice bearing 9464D-GD2 tumors. However, the key cellular mediators of CAIR and the relative importance of each component are not fully understood. In addition, there are limitations to this approach. First, in situ vaccination with RT and IT-IC results in protection against lung metastasis and rejection of tumor rechallenge in B78 melanoma. However, tumor cure of 9464D-GD2 neuroblastoma by CAIR fails to generate protective memory against tumor rechallenge, only slowing outgrowth of rechallenged 9464D-GD2 tumors, rather than preventing outgrowth. This incomplete memory suggests a less effective systemic adaptive response that may not treat distant 9464D-GD2 disease. Second, the development of CAIR required a dose reduction of hu14.18-IL2 in response to observed toxicity, suggesting that it is likely that this regimen could be associated with significant toxicity in patients. Understanding the mediators of efficacy in this combination immunotherapy regimen would allow for rational modifications that might improve the systemic immune response and decrease toxicity.

In this report, we identify key immune cell mediators responsible for the efficacy of CAIR (RT, IT-IC, anti-CD40, CpG, and anti-CTLA4) in mice bearing 9464D-GD2 neuroblastoma. Our data suggest that natural killer (NK) cells are a primary effector population responsible for the responsiveness of 9464D-GD2 tumors to CAIR and that their activity might be aided by very low expression of major histocompatibility complex class I (MHC-I) on the surface of 9464D-GD2 cells. Accordingly, we observed that increased MHC-I expression on tumors cells was associated with worse treatment outcomes in GD2-expressing 9464D models, suggesting that CAIR-induced NK cell activity can be suppressed by tumor expression of MHC-I and that this regimen generates a T cell response that is insufficient to fully compensate for the suppression of NK cells by MHC-I.

**METHODS**

**Cells**

The parental 9464D cell line is a MYCN-driven neuroblastoma cell line derived from TH-MYCN transgenic mice. 9464D-GD2 is a GD2-expressing cell line derived from 9464D as previously described. A subclone of the parental 9464D cell line selected for interferon-γ (IFN-γ)-inducible MHC-I expression was obtained by flow sorting and was subsequently transfected to express GD2 and GD3 syntheses (9464D-GD2-I). Cells were grown in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1X MEM non-essential amino acids, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cell lines were confirmed to be negative for mycoplasma by PCR prior to use.

**Murine tumor models**

All mice procedures were conducted in accordance with the Institutional Animal Care and Use Committee at the University of Wisconsin-Madison. Female mice aged 6–8 weeks were purchased from Taconic Biosciences (Germantown, New York, USA). R2G2 mice (B6;129-Rag2tm1WtsIl2rgtm1Rsky/DwHsd) were used for experiments requiring immunodeficient mice and were obtained from Envigo (Indianapolis, Indiana, USA). R2G2 mice are Rag2 and IL2RG double knockout mice that are deficient in B, T, and NK cells and relatively radioresistant. 9464D-GD2 flank tumors were engrafted by intradermal flank injection of 2×10⁶ tumor cells diluted in 100 µL phosphate buffered saline (PBS). Tumor size was determined by precision caliper measurement, and tumor volume was approximated using the formula (tumor volume in mm³=((tumor width in mm)×(tumor length in mm))×(tumor length in mm³)). Mice were randomized into treatment groups when tumors reached enrollment size (50 mm³). The first day of treatment with RT was defined as ‘day 1’. After injection, approximately 90% of mice had tumors at the time of randomization that were suitably uniform to enable similar tumor sizes among all randomized mice (ie, within the tumor volume range of 40–60 mm³); the remaining 10% of mice were excluded from randomization.

Flank tumor rechallenge experiments were performed with tumor-free mice approximately 40 days after treatment start unless otherwise indicated. Rechallenge consisted of intradermal injection of 2×10⁶ tumor cells on the contralateral flank from the original tumor cell injection. Tumor volume was assessed twice weekly and mice were euthanized when tumors exceeded 20 mm in any direction or mice were assessed to be in distress.
by changes to posture, activity, or grooming. In experiments where rechallenge was conducted in the setting of a primary tumor, mice that died of a rechallenge tumor before the primary tumor were censored with respect to primary tumor-related survival.

Radiotherapy
RT was delivered to primary tumors on day 1 of treatment using an Xstrahl Small Animal Radiation Research Platform (Suwanee, Georgia, USA). Mice were immobilized using custom lead jigs that exposed the dorsal right flank as previously described. For all experiments, a maximum dose of 12 Gy RT was delivered to the right flank tumor in one fraction.

Antibodies and IC
Hu14.18-IL2 IC was provided by Apeiron Biologics (Vienna, Austria) and has been previously described. Intratumoral (IT) injections of 25 µg hu14.18-IL2 IC in 100 µL PBS were delivered once daily for 5 days (days 6–10). Anti-mouse-CTLA-4 mAb (IgG2c isotype of the 9D9 clone) was provided by Bristol-Myers Squibb (Redwood City, California, USA) and was administered intraperitoneally (IP) at a dose of 200 µg in 0.2 mL PBS on day 3. CpG-oligodeoxynucleotide (TCCATATGCGTCCTGAGGTT) was purchased from TriLink Biotechnologies (San Diego, California, USA) or Integrated DNA Technologies (Coralville, Iowa, USA) and administered IT at a dose of 50 µg in 0.1 mL PBS on days 6, 8, and 12 as previously described. Anti-mouse-CD40 mAb was obtained from the ascites of nude mice injected with FGK 45.5 hybridoma cells producing agonistic anti-CD40 antibody (gift from Fritz Melchers, PhD, Basel Institute for Immunology, Basel, Switzerland). After enrichment for IgG, anti-CD40 mAb was administered IP at a dose of 500 µg in 0.2 mL PBS on day 3.

Depletion experiments
Depletion of NK cells was performed with IP injection of 100 µg anti-NK1.1 mAb (clone PK36, Bio X Cell, Lebanon, New Hampshire, USA) in 0.5 mL PBS on days –1, 3, 7, and 11. Depletion of T-cells was performed with IP injection of 400 µg anti-CD4 mAb (clone GK1.5, Bio X Cell) in 0.5 mL PBS and 400 µg anti-CD8 mAb (clone 2.43, Bio X Cell) in 0.5 mL PBS on days –1, 3, 7, and 11. Confirmation of depletion efficiency was performed via whole blood flow cytometry on day 1 (online supplemental figure 1).

MHC-I induction by IFN-γ
Expression of MHC-I antigens (H-2Kb and H-2Db) was assessed by flow cytometry using H-2Db-PE (clone KH95) and H-2Kb-BV711 (clone AF6-88.5) antibodies, both obtained from BioLegend (San Diego, California, USA). Induction of MHC-I expression in vitro was measured by flow cytometry following a 48-hour incubation in media containing 100 U/mL IFN-γ. Induction of MHC-I expression in vivo was measured by flow cytometry analysis of tumors harvested 7 days following the start of CAIR.

Flow cytometry
Mice were sacrificed on day 13 following initiation of radio-immunotherapy, and tumors were resected for analyses by flow cytometry or quantitative PCR (qPCR). Resected tumors were mechanically dissociated for 45 min using a gentleMACS disassociator (Miltenyi Biotec, Bergisch Gladbach, Germany) in HBSS supplemented with 1 mg/mL collagenase type D and 100 µg/mL DNase I (Sigma Aldrich, St. Louis, Missouri, USA) to obtain single cell suspensions. Ghost Dye Red 780 (Tonbo Biosciences, San Diego, California, USA) was used for viability staining. For cell surface staining, cells were preincubated with mouse Fc block (clone 2.4G2, BD Biosciences). After blocking, the cells were labeled with CD3-PE-Cy5 (clone 145–2 C11, BioLegend), CD4-PE-Dazzle594 (clone GK1.5, BioLegend), CD8a-APC-R700 (clone 53–6,7, BioLegend), CD25-BB515 (clone PC61, BD Biosciences, Franklin Lakes, New Jersey, USA), CD45-BV510 (clone 30-F11, BioLegend), CD2-APC (clone 14G2a, BioLegend), CD11b-BB700 (clone M1/70, BD Biosciences), F4/80-PE (clone BM8, BioLegend), Ly6G-BB711 (clone 1A8, BioLegend), and NK1.1-BV421 (clone PK136, BioLegend). Cells were then fixed and permeabilized overnight using Foxp3/Transcription Factor Staining Buffer Set (eBioscience). FoxP3 staining was then performed prior to flow cytometry (FoxP3-PE-Cy7, clone FJK-16s, BioLegend). Flow cytometry data were acquired using an Attune NxT Flow Cytometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and analyzed using FlowJo V.10.7.1 (FlowJo LLC, Ashland, OR). The flow cytometry gating strategy is shown in online supplemental figure 2.

RNA isolation and complementary DNA synthesis
RNA was isolated using a Trizol/RNeasy (Qiagen, Gilden, Germany) Hybrid protocol using Phase Lock Gels. In brief, cells were cultured in six-well plates as described. To harvest RNA, media was aspirated from each well and 1 mL of Trizol (Thermo Fisher Scientific) was added. After a 5 min incubation, cells were scraped with a sterile scraper, and lysates were transferred to Phase Lock tubes and incubated for 5 min at RT. Chloroform (200 µL) was added to each tube followed by vigorously shaking for 15 s. Samples were centrifuged at 12,000 × g for 10 min at 4°C. Supernatants were transferred to a new tube, and an equal volume of 100% ethanol was added to each sample and gently mixed. Samples were then transferred to RNeasy columns (RNeasy Mini Kit, Qiagen) and RNA was isolated according to kit instructions. RNA was eluted in 30 µl of RNase-free water into a 1.5 mL tube and stored at –80°C. Complement DNA was synthesized from 500 ng of RNA using SuperScript IV VILO MasterMix (Thermo Fisher Scientific) following the manufacturers protocol, followed by dilution in nuclease-free water 1:10 and then stored at –20°C.
The quantification of RNA was performed using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) containing TaqMan primers (H2-K1/H2-D1, Assay ID: Mm04208017_mH; Tap1, Assay ID: Mm00443188_m1; Tap2, Assay ID: Mm01277033_m1; PSMB9, Assay ID: Mm00479004_m1; B2m, Assay ID: Mm00437762_m1; NLRC5, Assay ID: Mm01243039_m1). Amplification of test genes were normalized to three internal control genes: Actb (Mm00607939_s1), Gadph (Mm99999915_g1), and Hprt (Mm00446968_m1).

qPCR was conducted at 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 95°C for 2 s and 60°C for 20 s. The threshold crossing value was noted for each transcript and normalized to the internal controls. The relative quantitation of each messenger RNA (mRNA) was performed using the comparative CT method. Experiments were performed using a QuantStudio 6 RealTime Flex PCR System (Thermo Fisher Scientific).

Statistical analysis

Tumor growth was monitored after treatment, and figures show the means and standard errors of the tumor volume. Results from each mouse were summarized by the time-weighted average (area under the volume-time curve, calculated using trapezoidal method). Time-weighted averages were compared between treatment groups overall by Kruskal-Wallis tests. If significance was found using the Kruskal-Wallis test, then pairwise comparisons were conducted using Mann-Whitney tests. No p value corrections were applied to these tests. Complete responders (cured mice) were indicated in figures as ***p<0.001; **p<0.01; *p<0.05; NS, not significant (p>0.05). All analyses were performed in duplicate. P values less than 0.05 were considered statistically significant and are indicated in figures as ***p<0.001; **p<0.01; *p<0.05; NS, non-significant (p<0.05). All analyses were performed using GraphPad Prism (GraphPad) or R V.4.0.5 (R Foundation for Statistical Computing).

RESULTS

CAIR treatment is effective in small 9464D-GD2 tumors and is associated with some toxicity

We previously described a combination radio-immunotherapy regimen (CAIR) that is effective in 9464D-GD2 tumors (figure 1A). We confirmed that this regimen is effective in prolonging survival (p<0.01) and curing mice bearing small (50 mm³) 9464D-GD2 tumors (4/5 mice tumor free, figure 1B). Larger (100 mm³) 9464D-GD2 tumors had prolonged survival (p=0.03) but were not cured by CAIR (0/5 mice tumor free, figure 1C). In addition, we confirmed that cured mice fail to reject rechallenge with 9464D-GD2 on the contralateral flank (figure 1D), although the growth of the rechallenged tumors is slower than tumor growth in paired naïve age-matched mice (p=0.01). In addition to limited efficacy against larger 9464D-GD2 tumors, CAIR is associated with moderate toxicity. To determine which components of the regimen are responsible for efficacy and toxicity, we tracked weight and survival of variants of the regimen (figure 1E). For all three regimens, following the addition of other agents to RT, we observed substantial weight loss from days 5–10. We observed similar efficacy under these conditions when anti-CTLA4 was omitted, suggesting that alleviation of immune suppression by T regulatory cells is not required for CAIR efficacy in this model. Individual tumor growth curves for the data included in figure 1E are shown in online supplemental figure 3A. These findings demonstrate that while CAIR can cure a significant number of mice bearing small 9464D-GD2 tumors, there is significant potential for improvement which might be informed by further examination of the mechanisms driving CAIR efficacy.

NK cells play a significant role in CAIR-mediated tumor cures but are not required for early tumor regression

To determine which immune subsets are involved in the response to CAIR for 9464D-GD2, we assessed treatment response in immunodeficient mice and mice depleted of specific immune subsets. We first tested the response to CAIR in immunodeficient R2G2 mice, which lack T, B, and NK cells and have decreased macrophages, dendritic cells, and neutrophils. These 9464D-GD2 tumor-bearing R2G2 mice had superior tumor response with CAIR compared with RT treated or vehicle controls (p<0.01 and p<0.01, respectively, figure 2A). However, after this initial reduction in tumor size during the first ~30 days following CAIR, the majority of R2G2 mice had tumor regrowth/escape by 100 days after the start of therapy (0/7 mice tumor free, figure 2A). Immunocompetent C57BL/6 mice treated with CAIR also had improved tumor response relative to RT treated or vehicle controls (p<0.01 and p<0.01, respectively, figure 2B), though the majority of mice were cured (4/5 mice tumor free). Individual tumor growth curves are shown in online supplemental figure 3B. These data demonstrate that early response to CAIR by 9464D-GD2 tumors is not driven by T, B, or NK cells and suggest, conversely, that late tumor control might depend on one or more of the populations of cells deficient in R2G2 mice.

To determine whether NK or T cells were responsible for preventing delayed outgrowth, and enabling cures of tumors treated with CAIR, we next performed antibody depletion experiments (figure 2C, online supplemental figure 1). As in previous experiments, 9464D-GD2 tumors treated with vehicle controls or radiation grew substantially during the first 30 days. In contrast, tumors treated with CAIR or CAIR with NK, T, or NK and T cell depletion regressed with superimposable growth curves.
during this period (figure 2D, online supplemental figure 3C), confirming that NK and T cells are not responsible for early tumor regression. However, while roughly half of CAIR-treated, non-depleted, mice developed lasting tumor cures, all mice depleted of both NK and T cells developed tumor outgrowth and were culled (figure 2E–F). Similarly, nearly all CAIR-treated mice depleted of only NK cells also showed delayed tumor outgrowth in this late period, resulting in significantly decreased survival compared with CAIR-treated IgG controls (p<0.05). CAIR-treated mice depleted of only T cells followed a similar pattern as those depleted of NK cells, but the survival difference was not statistically significant compared with IgG controls (p=0.16).

NK cell activity in tumors is regulated by a variety of receptor-ligand interactions, including the binding of inhibitory receptors (KIRs in humans and Ly49 in mice) to cognate MHC-I molecules. In light of the data indicating that NK cells have a significant role in CAIR-mediated tumor cures, we hypothesized that 9464D-GD2 cells might express very low levels of MHC-I, allowing for NK cell-mediated elimination of tumors.

9464D-GD2 cells fail to express MHC-I in response to IFN-γ

MHC-I molecules play multiple roles in the interactions between cancer cells and infiltrating immune cells. In addition to NK cell inhibition, MHC-I expression by cancer cells is required for CD8+ T cells to recognize cognate antigens at the tumor site after priming by antigen presenting cells in draining lymph nodes. To determine the role of tumor MHC-I in the immune response to CAIR, we assessed MHC-I expression on parental 9464D and 9464D-GD2 cells in vitro. We found that the 9464D cells express very little surface MHC-I at baseline; however, following stimulation with IFN-γ, a potent cytokine known to induce MHC-I though ligation with its receptor IFN-γR, roughly 25% of cells express significant levels of its two murine MHC-I genes, H-2Db and H-2Kb (figure 3A). Conversely, 9464D-GD2 expressed very little MHC-I both at baseline and after incubation with IFN-γ (figure 3B). This difference indicates that when cells from the parental cell line were transfected to express GD2, a subclone lacking MHC-I inducibility was unintentionally selected to generate the new cell line. To determine the source of MHC-I presentation dysfunction,
transcription of genes related to antigen presentation and MHC expression was quantified in both 9464D and 9464D-GD2 (figure 3C). Accordingly, we observed that TAP1 and PSMB9 transcription was not upregulated in 9464D-GD2 cells following incubation with IFN-γ, in contrast to the prominent upregulation of both of these when the parental 9464D cell line was incubated with IFN-γ. TAP1 and PSMB9 share a common bi-directional promoter in humans and mice, suggesting that regulation of this promoter region might contribute to the lack of MHC-I inducibility in 9464D-GD2 cells.12 13

MHC-I expressing 9464D-GD2 cells are resistant to tumor cure by CAIR

CD8+ T cells are unable to recognize and respond to tumor cells that do not have MHC-I expression. To assess the impact of tumor cell expression of MHC-I on responsiveness to CAIR, we developed a separate cell line from a subclone of the parental 9464D cell line capable of upregulating MHC-I in response to IFN-γ by transfecting it to express GD2 and GD3 synthases (9464D-GD2-I) (figure 4A). To confirm that 9464D-GD2-I expression of MHC-I could be induced in vivo, we examined these tumor cells by flow cytometry after in vivo growth followed by CAIR treatment. We observed that 9464D-GD2-I, but not 9464D-GD2, effectively upregulated expression of MHC-I in response to treatment in mice (figure 4B). To determine if this difference in MHC-I induction correlated with tumor infiltration of NK or CD8+ T cells, we harvested tumors 13 days after the start of CAIR treatment. We found that in both 9464D-GD2-I and 9464D-GD2 tumors, CD8+ T cell infiltration in CAIR-treated mice increases as a percentage of live cells (figure 4C). Similarly, both types of CAIR-treated tumors appeared to have increased infiltration of NK cells at this time point, although the shift was
not statistically significant in 9464D-GD2 tumors. These data indicate that while MHC-I inducibility is retained in vivo in 9464D-GD2-I and its expression is upregulated in response to CAIR, tumor recruitment or retention of NK and T cells is not necessarily enhanced by this difference compared with the MHC-I non-inducible 9464D-GD2 tumors.

To assess if MHC-I upregulation correlated with increased responsiveness of GD2-expressing 9464D tumors to CAIR, we monitored tumor growth and survival in response to treatment (figure 4D–F). As before, we observed that both 9464D-GD2-I and 9464D-GD2 tumors showed similar regression in the first 30 days after treatment initiation, suggesting that MHC-I does not impact the early response of tumors to CAIR (figure 4E). However, after this early period, tumor growth diverged and mice bearing 9464-GD2-I tumors had fewer cured mice than mice bearing 9464D-GD2 tumors (6/17 mice vs 13/19 mice tumor free, p<0.05, figure 4D). Additionally, 9464D-GD2-I tumors regrew more quickly and had worse survival than 9464D-GD2 tumors (figure 4E–F, online supplemental figure 4), suggesting that tumor-reactive cells which are typically suppressed by MHC-I expression (NK cells and possibly macrophages) are responsible for slowing the growth of recurrent tumors. Together, these data support the conclusion that NK cells, rather than CD8+ T cells, drive 9464D-GD2 responsiveness to CAIR and that this NK response is aided by low or absent MHC-I expression on tumor cells.

**DISCUSSION**

The results of this study provide insights regarding the mechanism of our recently described combination radio-immunotherapy regimen targeting innate and adaptive immunity (CAIR) in the immunologically cold 9464D-GD2 model of neuroblastoma. The initial response (substantial tumor shrinkage up through 30 days) does not appear to be mediated by NK or T cell populations. In contrast, NK cells are substantially involved in tumor cures by CAIR and might have a role in slowing tumor regrowth after recurrence. This finding is consistent with our observation that MHC-I is not expressed by 9464D-GD2 tumor cells in vitro or in vivo, and thus would not be expected to interfere with NK function via ligation of inhibitory Ly-49 receptors. When CAIR was applied in mice bearing tumors capable of MHC-I induction (9464D-GD2-I), the treatment was similarly effective in causing initial tumor...
shrinkage; however, CAIR was significantly more effective at clearing tumors completely and slowing tumor outgrowth in mice bearing the MHC-I non-inducible 9464D-GD2-I tumors than for mice with the MHC inducible 9464D-GD2-I tumors. These differences might be explained by the inhibition of NK cell function, a primary effector population, by MHC-I, combined with the insufficiency of the regimen to generate an effective CD8+ T cell response to fill in the gap in antitumor immune activity against the 9464D-GD2-I tumors.

MHC-I expression is absent or very low in nearly all high-risk clinical neuroblastoma tumors and is thought to contribute to an immunosuppressive tumor microenvironment. One study demonstrated that primary human neuroblastomas are similarly associated with low expression of antigen presentation machinery. Another study of human neuroblastoma cell lines found that of 11 commonly used cell lines, 9 expressed very low levels of mRNA related to antigen presentation on MHC-I. This lack of MHC expression on human neuroblastomas may be driven in part by MYCN amplification, which is associated with high-risk disease and with low expression of MHC-I and poor infiltration of T cells into the tumor microenvironment. Similarly, the MYCN-overexpressing preclinical mouse models of neuroblastoma, such as 9464D and other TH-MYCN driven models, have previously been shown to express low levels of MHC-I and be minimally infiltrated by T cells. In some neuroblastoma cell lines with low baseline MHC-I expression, MHC-I can be induced by IFN-γ stimulation. However, this does not necessarily improve treatment response. While potentially increasing T cell recognition, induction of MHC-I has been shown to result in decreased sensitivity to NK-mediated cytotoxicity. Accordingly, we have previously demonstrated that upregulation of MHC-I on NXS2 neuroblastoma cells can mediate escape from NK-driven immunotherapy in vivo by inhibiting NK cell function.

Expression of antigens on MHC-I molecules is an intricate process requiring cleavage of intracellular proteins by the proteasome or immunoproteasome, translocation of peptides through TAP channels in the endoplasmic reticulum (ER) membrane, trimming of peptides in the ER, and loading of high-affinity peptides before translocation to the cell surface. As a result, interference with any of these steps can inhibit cell surface expression of MHC-I. Common methods of MHC-I downregulation by tumors include epigenetic dysregulation of genes relating to antigen presentation and, more rarely, selection for mutations of these genes. Through a mechanism not yet understood, the data presented here demonstrate that...
expression of TAP1 and PSMB9, genes responsible for cleavage and translocation of peptides into the ER, are dysregulated in 9464D-GD2. Similarly, loss of TAP1 and PSMB9 induction has been linked to the loss of MHC-I expression in models of renal cell carcinoma and leiomyosarcoma. Expression of these genes is linked by a common bi-directional promotor that is induced by IFN-γ via IRF2 and STAT1. Accordingly, defects in the IFN-γ response pathway have also been linked to loss of MHC-I expression by cancer cells. It is not yet clear if the lack of TAP1 and PSMB9 inducibility by IFN-γ is solely, or directly, responsible for low MHC-I expression on 9464D-GD2 or how expression of these genes is dysregulated. Future studies will aim to clarify this association and identify the mechanism by which TAP1 and PSMB9 are suppressed in 9464D-GD2. Further analyses of the regulation of these pathways, possibly via epigenetic modulation, may help determine whether this observation has relevance for human disease and potential therapeutic strategies to engage CD8+ T cells.

In this study we demonstrated that early regression of 9464D-GD2 and 9464D-GD2-I tumors following CAIR treatment was not solely mediated by radiotherapy, indicating that the initial response is driven by the immunotherapy component of CAIR. We demonstrated that NK and T cells were not required for early tumor response, suggesting that non-lymphocyte populations drive the early antitumor response of these tumors to CAIR. Previously, we published a study showing that CD40 agonism combined with CpG, two components of CAIR, can mediate tumor regression via infiltration of tumoricidal macrophages and macrophage repolarization. Our prior report also demonstrated that anti-CD40 and/or CpG are required for the responsiveness of 9464D-GD2 tumors to CAIR, suggesting that this mechanism might play a role in curing 9464D-GD2 tumors. Preliminary data from ongoing studies in our lab are suggestive of a potential role for macrophages in the early response to this CAIR regimen. Further work is underway to address this question in a separate report.

Even though the tumor response data demonstrate that T cells are not required in the early tumor response to CAIR, analysis of immune cells infiltrating into these tumors show an increase in infiltrating CD4+ and CD8+ T cells correlating with the increase in infiltrating NK cells. The increased infiltration of lymphocyte populations into tumors after CAIR suggests that this treatment results in the secretion of chemokines, which is driven by pro-inflammatory signaling. This pro-inflammatory environment may be aided in part by the demonstrated depletion of T regulatory cells by CAIR, likely by the anti-CTLA4 component of the regimen. Taken together, these results indicate that while T cells may not have a significant role in the early tumor response, CAIR treatment drives their recruitment, suggesting that corresponding induction of MHC-I with additional alleviation of immune suppression might further support antitumor T cell activity. Thus, the role of anti-CTLA4, which does not appear to have a significant role in tumor shrinkage in this model, might change substantially if further changes are made to the CAIR regimen that increase the T cell mediated antitumor effect.

**Conclusion**

We show here that in the 9464D-GD2 model of neuroblastoma, NK cells are a primary effector population driving tumor cures and slowing tumor escape from our combination radio-immunotherapy regimen, CAIR. This conclusion is supported by reduced efficacy of CAIR after antibody depletion of NK cells and the finding that the inducible expression of MHC-I in 9464D-GD2-I corresponds to fewer tumor cures and more rapid tumor outgrowth. Future studies should explore the role of myeloid cells in the treatment response, the ability to potentially modulate MHC class-I expression in vivo to drive an effective CD8+ T cell response, and the relevance of this model to human disease.

**Author affiliations**

1Department of General Surgery, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, USA
2Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA
3Provenance Biopharmaceuticals, Carlisle, Massachusetts, USA
4Biosciences and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA
5Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA

**Contributors** TA performed experiments, analyzed and interpreted data, and was the primary author of this manuscript. AE, ASF, and LZ designed and conducted experiments representing multiple figures in the manuscript. DK, MR, and AS assisted in animal studies, including drug administration and tumor measurements. ASF and AE assisted in flow cytometry. JB assisted with statistical analyses. SDG originally created the immunocytokine and the antibody studied. TA, AE, ALR, ZM, and PMS were key contributors to the experimental concept and design. PMS was the guarantor of the study. All authors contributed to the writing of the manuscript and approved the final manuscript.

**Funding** This work was supported by Midwest Athletes Against Childhood Cancer; Stand Up 2 Cancer; the St. Baldwin’s Foundation; the Crawforduddy Foundation; the University of Wisconsin Carbone Cancer Center, and the Children’s Neuroblastoma Cancer Foundation. This research was also supported in part by public health service grants T32 CA090217, U54-CA232568, R35-CA197078, U01-CA233102, and Project 3 of P01CA250972 from the National Cancer Institute; and UL1TR002373 from the National Institutes of Health and the Department of Health and Human Services. Shared resource flow cytometry reagents and equipment are funded by University of Wisconsin Carbone Cancer Center Support Grant P30-CA014520. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Competing interests** SDG declares employment and ownership interests in Provenance Biopharmaceuticals.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,
terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Taylor J Aiken http://orcid.org/0000-0003-1139-9822
Alexander L Rakhmilevich http://orcid.org/0000-0002-2686-9500
Paul M Sondel http://orcid.org/0000-0002-0981-8875

REFERENCES